Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Ascentage Pharma Group Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05701306CT.gov APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lisaftoclax (this asset) | Ascentage Pharma Group Inc. | P1 | CC · 41 |
| Etoposide | M.D. Anderson Cancer Center | P2/3 | BB |
| Nivestim | M.D. Anderson Cancer Center | P4 | BB |
| Cyclophosphamide | Robbie Majzner | P2 | BB |
| Melphalan | M.D. Anderson Cancer Center | P2/3 | BB |
| Carboplatin | St. Jude Children's Research Hospital | P2/3 | BB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Irinotecan | Milton S. Hershey Medical Center | P2 | BB |
| Adriamycin | Hoffmann-La Roche | P2 | BB |
+42 more in the Neuroblastoma cohort
Other indications for Lisaftoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BBB · 73 |
| Acute Myeloid Leukemia | — | P3 | B · 63 |
| Diffuse Large B-Cell Lymphoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lisaftoclax in Neuroblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lisaftoclax-neuroblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →